Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Takeda Oncology, Genomic Health, and Novartis.

Community Practice Connections™: 2nd Annual European Congress on Immunotherapies in Cancer™


Release Date: January 31, 2018
Expiration Date: January 31, 2019
Media: Internet - based

 

Activity Overview

This activity focuses on immunotherapies in renal cell carcinoma, non–small cell lung cancer, and B-cell malignancies. It consists of a series of brief video interviews with leading experts and short summaries of clinical data related to issues discussed in the interviews. The content and videos are based on presentations given at the 2nd Annual European Congress on Immunotherapies in Cancer™, held September 22-23, 2017, in Barcelona, Spain. The program is designed for community oncologists, and addresses current standards of care and emerging concepts in cancer immunotherapy.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Takeda Oncology, Genomic Health, and Novartis.

CME/CE Activity Table of Contents

  • Module 1: Emerging Immunotherapeutic Strategies in Renal Cell Carcinoma
    Bernard Escudier, MD
  • Module 2: Is PD-L1 Expression a Useful Biomarker for Checkpoint Inhibitor Treatment in Patients With Lung Cancer?
    Roman Perez-Soler, MD
  • Module 3: Building a Better Chimeric Antigen Receptor T Cell
    Michel Sadelain, MD, PhD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is intended for medical oncologists and other healthcare professionals (eg, physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants). Participants will primarily be those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain mechanistic approaches toward targeting the immune system to treat cancer
  • Evaluate the clinical applicability of data from clinical trials of immunotherapy strategies
  • Discuss methods to individualize the use of immunotherapy strategies, including the use of biomarkers
  • Describe how to proactively mitigate and manage adverse events associated with the use of treatment strategies in the care of patients with cancer
  • Identify unmet clinical needs in cancer treatment and highly anticipated clinical trials evaluating novel immunotherapeutic approaches

Faculty, Staff, and Planners' Disclosures

Faculty

Bernard Escudier, MD
Chair, Genitourinary Oncology Committee
Gutave Roussy
Paris, France
 
 

Disclosure: Consultant/Advisory Boards: Pfizer, Novartis, Bristol-Myers Squibb, Roche, Exelixis, Ipsen

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, New York, USA

Disclosure: Consultant/Advisory Boards: AstraZeneca, Clovis, Roche/Genentech, Boehringer Ingelheim, Lilly, Adgero

Michel Sadelain, MD, PhD
Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory
Stephen and Barbara Friedman Chair
Memorial Sloan Kettering Cancer Center
New York, New York, USA

Disclosure: Consultant/Advisory Boards: Juno Therapeutics

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.




PER Pulse™ Recap (1 of 3)

Community Practice Connections™: 2nd Annual European Congress on Immunotherapies in Cancer™ is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in September 2017 in Barcelona, Spain. In this online activity, expert faculty discuss aspects of immunotherapy important to cancer care providers. It features commentary on:

  • Emerging Immunotherapeutic Strategies in Renal Cell Carcinoma
    Bernard Escudier, MD
  • Is PD-L1 Expression a Useful Biomarker for Checkpoint Inhibitor Treatment in Patients With Lung Cancer?
    Roman Perez-Soler, MD
  • Building a Better Chimeric Antigen Receptor T Cell
    Michel Sadelain, MD, PhD

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on an interview with Dr Escudier about important recent developments in immunotherapy for renal cell carcinoma (RCC), during which he discussed the rationale for combining immunotherapy with targeted therapies (eg, VEGF tyrosine kinase inhibitors) or other immunotherapeutic agents, results from the CheckMate-214 trial that he presented at ESMO 2017 and their potential impact on frontline decision making, as well as the status of the quest for reliable predictive biomarkers in RCC.




PER Pulse™ Recap (2 of 3)

Community Practice Connections™: 2nd Annual European Congress on Immunotherapies in Cancer™is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in September 2017 in Barcelona, Spain. In this online activity, expert faculty discuss aspects of immunotherapy important to cancer care providers. It features commentary on:

  • Emerging Immunotherapeutic Strategies in Renal Cell Carcinoma
    Bernard Escudier, MD
  • Is PD-L1 Expression a Useful Biomarker for Checkpoint Inhibitor Treatment in Patients With Lung Cancer?
    Roman Perez-Soler, MD
  • Building a Better Chimeric Antigen Receptor T Cell
    Michel Sadelain, MD, PhD

This second of 3 PER Pulsev™ Recaps summarizing the online program focuses on an interview with Dr. Perez-Soler about the value of PD-L1 expression to guide use of checkpoint inhibitory therapy in non–small-cell lung cancer (NSCLC), during which he discussed recent data in this area, varying perspectives regarding the use of PD-L1 testing in NSCLC, his own approach to PD-L1 testing, additional biomarkers for NSCLC, and best practices in selecting a checkpoint inhibitor for your patients with NSCLC.




PER Pulse™ Recap (3 of 3)

Community Practice Connections™: 2nd Annual European Congress on Immunotherapies in Cancer™ is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in September 2017 in Barcelona, Spain. In this online activity, expert faculty discuss aspects of immunotherapy important to cancer care providers. It features commentary on:

  • Emerging Immunotherapeutic Strategies in Renal Cell Carcinoma
    Bernard Escudier, MD
  • Is PD-L1 Expression a Useful Biomarker for Checkpoint Inhibitor Treatment in Patients With Lung Cancer?
    Roman Perez-Soler, MD
  • Building a Better Chimeric Antigen Receptor T Cell
    Michel Sadelain, MD, PhD

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on an interview with Dr. Sadelain about chimeric antigen receptor (CAR) T therapy, during which he discussed the rationale for targeting CD19 in B-cell malignancies, the central tenets of CAR therapy, how CAR design has evolved since its inception, new techniques being employed to identify CAR targets, potential applications for engineered T cells, recent data from CAR studies that he finds exciting, key safety concerns, state-of-the-art approaches toward improving the potency of CAR T therapies, and ongoing trials.








Become a Member

Forgot Password?
Filter By